NASDAQ:EFTR

Effector Therapeutics Stock Signals

etoro logo Buy EFTR
*Your capital is at risk
$0.0006
+0 (+0%)
At Close: Jun 03, 2026

Latest Data & Signals Issued

Below are some of the latest signals issued for eFFECTOR Therapeutics, Inc.

General

Signal Type Signal Value Data
Score 0.000 87 days ( -200.00 %
Last Price $0.0006 0 %
Performance History
7 Days
$0.0002 $0.0006
200.00%
30 Days
$0.0002 $0.0006
200.00%
12 Mos
$0.0002 $0.0006
200.00%

3/18

Active Buy Signals

Specific Signals

Short Term
Net score: 25
Signal Type Signal Value Importance Data
High / Low N/A Very Low $0.0006 - $0.0006
Trend - 3 mos 52.50 % High Width: 178.68 %
Pred. range - 3 mos $0.0003 - $0.0009 Low -44.98 % - 53.34 %
Volume Direction Sell High Volume: 1,153 · Direction: 0
Pivot Short Sell Very Low Jun 02, 2026 - 2 days
RSI Short Pivot Signal Sell Very Low May 28, 2026 - 5 days
Short MA 3 mos Sell Low Mar 10, 2026 - 60 days
Long MA 3 mos Sell Medium May 26, 2026 - 7 days
Short/Long MA 3 mos Sell Medium Mar 17, 2026 - 55 days

Unlock Short Term Signals

Get access to powerful short-term trading signals and real-time market insights

Subscribe Now
Long Term
Net score: 25.59
Signal Type Signal Value Importance Data
Trend - 12 mos -0.403 % Very High Width: 28,230.19 %
Pred. range - 12 mos N/A - $1.49 High -100.00 % - 248,320.70 %
Short MA 12 mos Sell Very High May 26, 2026 - 7 days
Long MA 12 mos Sell Very High May 26, 2026 - 7 days
Short/Long MA 12 mos Buy Very High May 11, 2026 - 17 days
Pivot Long Sell Low Jun 02, 2026 - 2 days
RSI Long Pivot Signal Buy Low Dec 18, 2025 - 114 days
Bollinger Sell Medium Nov 30, -0001 - N/A days
MACD Sell High No Dates Stored For This Signal
Click to get the best stock tips daily for free!
ABOUT EFFECTOR THERAPEUTICS, INC.
eFFECTOR Therapeutics
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit euk...
GOLDEN STAR
Ticker Change Signal Date
RUN
$12.83
18.86% May 06
GLBE
$31.61
5.35% May 05
SAP
$172.39
10.69% May 05
W
WCLD
$27.34
27.18% Apr 29
ADBE
$243.57
7.61% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE